Neurotrope Inc (NASDAQ:NTRP) reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as $4.74 and last traded at $5.48, with a volume of 100 shares trading hands. The stock had previously closed at $5.66.

NTRP has been the subject of several research analyst reports. Maxim Group reaffirmed a “buy” rating and set a $16.00 price target on shares of Neurotrope in a research note on Monday, August 13th. Zacks Investment Research raised Neurotrope from a “hold” rating to a “buy” rating and set a $11.00 price target for the company in a research note on Friday, August 17th.

Neurotrope (NASDAQ:NTRP) last issued its quarterly earnings results on Tuesday, October 30th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.45) by $0.05.

A number of hedge funds have recently modified their holdings of the business. Cannell Peter B & Co. Inc. lifted its stake in Neurotrope by 3.7% during the third quarter. Cannell Peter B & Co. Inc. now owns 280,793 shares of the company’s stock worth $2,474,000 after purchasing an additional 10,000 shares during the last quarter. Ingalls & Snyder LLC increased its holdings in shares of Neurotrope by 38.9% in the third quarter. Ingalls & Snyder LLC now owns 46,800 shares of the company’s stock worth $412,000 after buying an additional 13,100 shares during the period. Renaissance Technologies LLC increased its holdings in shares of Neurotrope by 72.4% in the third quarter. Renaissance Technologies LLC now owns 50,000 shares of the company’s stock worth $441,000 after buying an additional 21,000 shares during the period. Tanaka Capital Management Inc. increased its holdings in shares of Neurotrope by 12.1% in the second quarter. Tanaka Capital Management Inc. now owns 198,195 shares of the company’s stock worth $1,919,000 after buying an additional 21,455 shares during the period. Finally, Pathstone Family Office LLC purchased a new position in shares of Neurotrope in the third quarter worth about $270,000. 18.17% of the stock is owned by hedge funds and other institutional investors.

WARNING: “Neurotrope (NTRP) Sets New 52-Week Low at $4.74” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at https://www.watchlistnews.com/neurotrope-ntrp-sets-new-52-week-low-at-4-74/2671127.html.

Neurotrope Company Profile (NASDAQ:NTRP)

Neurotrope, Inc, a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease (AD). Its lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. The company also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X and Niemann-Pick Type C.

Featured Article: What is a Stop Order?

Receive News & Ratings for Neurotrope Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurotrope and related companies with MarketBeat.com's FREE daily email newsletter.